Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Decreasing Time to Initiation of Chemotherapy for Patients Electively Admitted to a Hematologic Malignancy Service.

Authors:
Jose N Galeas Stuart Packer Roy Browne Susan Sakalian Adam F Binder

J Oncol Pract 2019 10 8;15(10):e906-e915. Epub 2019 Aug 8.

Thomas Jefferson University Hospital, Philadelphia, PA.

Purpose: Delays in initiating elective inpatient chemotherapy can decrease patient satisfaction and increase length of stay. At our institution, we observed that 86% of patients who were admitted for elective chemotherapy experienced a delay-more than 6 hours-with a median time to chemotherapy of 18.9 hours. We developed a process improvement initiative to improve time to chemotherapy for elective chemotherapy admissions.

Methods: Our outcome measure was the time from admission to chemotherapy administration in patients who were admitted for elective chemotherapy. Process measures were identified and monitored. We collected baseline data and used performance improvement tools to identify key drivers. We focused on these key drivers to develop multiple plan-do-study-act cycles to improve our outcome measure. Once we started an intervention, we collected data every 2 weeks to assess our intervention.

Results: At the time of interim analysis, we observed a median decrease in time to chemotherapy administration from 18.9 hours to 8.85 hours ( = .005). Median time to laboratory results resulted decreased from 3.17 hours to 0.00 hours. There was no change in time from signing chemotherapy to nurse releasing the chemotherapy. We noted that more providers were signing the chemotherapy before patient admission.

Conclusion: By implementing new admission workflows, optimizing our use of the electronic medical record to communicate among providers, and improving preadmission planning we were able to reduce our median time to chemotherapy for elective admissions by 53.2%. Improvement is still needed to meet our goals and to ensure the sustainability of these ongoing efforts.

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00120DOI Listing
October 2019

Publication Analysis

Top Keywords

time chemotherapy
16
chemotherapy
13
median time
12
elective chemotherapy
12
time
8
key drivers
8
admitted elective
8
outcome measure
8
chemotherapy administration
8
patients admitted
8
signing chemotherapy
8
chemotherapy elective
8
189 hours
8
hours
5
elective
5
change time
4
analysis observed
4
monitored collected
4
process measures
4
measures identified
4

Altmetric Statistics


Show full details
14 Total Shares
1 News Outlets
10 Tweets
11 Citations

Similar Publications

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications.

Authors:
M G Krebs J-Y Blay C Le Tourneau D Hong L Veronese M Antoniou I Bennett

ESMO Open 2021 Mar 3;6(2):100072. Epub 2021 Mar 3.

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Background: Entrectinib is a tropomyosin receptor kinase inhibitor approved for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours based on single-arm trials. Traditional randomised clinical trials in rare cancers are not feasible; we conducted an intrapatient analysis to evaluate the clinical benefit of entrectinib versus prior standard-of-care systemic therapies.

Methods: Patients with locally advanced/metastatic NTRK fusion-positive tumours enrolled in the global phase II, single-arm STARTRK-2 trial were grouped according to prior systemic therapy and response. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Comprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs.

Authors:
Aditi Chauhan Manoj Kumar Awanish Kumar Kajal Kanchan

Life Sci 2021 Mar 3:119301. Epub 2021 Mar 3.

Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Noida 201313, India. Electronic address:

Tuberculosis is one of the deadliest infectious diseases existing in the world since ancient times and still possesses serious threat across the globe. Each year the number of cases increases due to high drug resistance shown by Mycobacterium tuberculosis (Mtb). Available antimycobacterial drugs have been classified as First line, Second line and Third line antibiotics depending on the time of their discoveries and their effectiveness in the treatment. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib.

Authors:
Roberta Minari Alessandro Leonetti Letizia Gnetti Teresa Zielli Luigi Ventura Lorena Bottarelli Costanza Lagrasta Silvia La Monica Pier Giorgio Petronini Roberta Alfieri Marcello Tiseo

Anticancer Drugs 2021 Mar 5. Epub 2021 Mar 5.

Medical Oncology Unit Pathology Unit, Department of Medicine and Surgery Thoracic Surgery, Department of Medicine and Surgery Department of Medicine and Surgery, University of Parma, Parma, Italy.

Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used both as the first-line treatment of EGFR-mutated non-small cell lung cancer patients and in second-line after T790M-positive disease progression to first- or second-generation TKIs. Unfortunately, patients unavoidably experience disease progression to osimertinib and the current research is focused on resistance mechanisms and the relative therapeutic strategy. We report the case of a patient with advanced EGFR-mutated (exon 19 deletion and T790M-positive) non-small cell lung cancer who developed disease progression to osimertinib characterized by the loss of T790M concurrently with the emergence of G724S EGFR mutation, which was tackled by subsequent afatinib treatment. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Long-term outcomes of high-dose (74 GyE) proton beam therapy with concurrent chemotherapy for stage III nonsmall-cell lung cancer.

Authors:
Kayoko Ohnishi Hitoshi Ishikawa Kensuke Nakazawa Toshihiro Shiozawa Yutaro Mori Masatoshi Nakamura Toshiyuki Okumura Ikuo Sekine Nobuyuki Hizawa Hideyuki Sakurai

Thorac Cancer 2021 Mar 6. Epub 2021 Mar 6.

Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Background: To evaluate the long-term outcomes of high-dose (74 GyE) proton beam therapy (PBT) with concurrent chemotherapy for stage III non-small cell lung cancer (NSCLC).

Methods: Between July 2007 and March 2018, 45 patients with stage III NSCLC were treated with passive-scattering PBT of 74 GyE and concurrent chemotherapy. Among the 45 patients, the median age was 62 years (range 39-79 years) and 32 patients were men. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.

Authors:
Yugo Chisaki Yoshiki Kuwada Chikako Matsumura Yoshitaka Yano

Clin Drug Investig 2021 Mar 5. Epub 2021 Mar 5.

Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical University, 5-Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto, 607-8414, Japan.

Background And Objectives: Atezolizumab is an anti-programmed death ligand 1 (PD-L1) antibody that shows good safety and efficacy for patients with PD-L1-positive triple-negative breast cancer (TNBC). The cost of atezolizumab therapy is expensive, and its economic burden is an important problem. In this study, we evaluated the cost effectiveness of atezolizumab plus nab-paclitaxel therapy (AnP) compared with nab-paclitaxel monotherapy (nP) for PD-L1-positive TNBC under Japanese medical conditions and environments using a Markov model. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap